AI Article Synopsis
Article Abstract
Purpose: Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence of activity in sarcomas. This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas.
Patients And Methods: Patients with metastatic or unresectable soft tissue or bone sarcomas received ridaforolimus 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks. The primary end point was clinical benefit response (CBR) rate (complete response or partial response [PR] or stable disease ≥ 16 weeks). Safety, progression-free survival (PFS), overall survival (OS), time to progression, and duration of response were also evaluated.
Results: A total of 212 patients were treated in four separate histologic cohorts. In this heavily pretreated population, 61 patients (28.8%) achieved CBR. Median PFS was 15.3 weeks; median OS was 40 weeks. Response Evaluation Criteria in Solid Tumors (RECIST) confirmed response rate was 1.9%, with four patients achieving confirmed PR (two with osteosarcoma, one with spindle cell sarcoma, and one with malignant fibrous histiocytoma). Archival tumor protein markers analyzed were not correlated with CBR. Related adverse events were generally mild or moderate and consisted primarily of stomatitis, mucosal inflammation, mouth ulceration, rash, and fatigue.
Conclusion: Single-agent ridaforolimus in patients with advanced and pretreated sarcomas led to PFS results that compare favorably with historical metrics. A phase III trial based on these data will further define ridaforolimus activity in sarcomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2011.35.6329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials.
J Am Heart Assoc
November 2024
Department of Cardiology, Tel Aviv Sourasky Medical Center, Affiliated with the School of Medicine Tel Aviv University Tel Aviv Israel.
Article Synopsis
- The BIONICS and NIREUS trials compared the ridaforolimus-eluting stent (RES) and zotarolimus-eluting stent (ZES), showing that RES was noninferior to ZES for 1-year target-lesion failure and 6-month lumen loss.
- A pooled analysis of 2221 patients over 5 years found similar rates of target-lesion failure (12.2% for RES vs 11.3% for ZES), with no significant differences in other outcomes like myocardial infarction or stent thrombosis.
- Although the RES group had higher rates of target-vessel revascularization and cardiac death, these differences were not significant after adjusting for patient characteristics, indicating long-term
Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
J Am Heart Assoc
January 2024
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute Queen Mary University of London and Barts Heart Centre London United Kingdom.
Article Synopsis
- * A study involving 315 patients found that after 1 year, only 4.9% experienced serious events like cardiac death or stent thrombosis, which was better than the pre-set safety target.
- * The results indicate that a 1-month DAPT is sufficient for patients with stable angina, and some acute coronary syndrome patients had DAPT extended to 3 months, with very low rates of complications.
Percutaneous coronary intervention with ridaforolimus eluting-stents in small vessel coronary artery disease.
Catheter Cardiovasc Interv
January 2024
Cardiology Department, Meir Medical Center, Kfar Saba, Israel.
Article Synopsis
- The ridaforolimus-eluting stent (RES) system, known as EluNIR, uses a unique cobalt alloy and polymer to treat small coronary artery disease with a diameter of 2.25 mm.
- The study assessed safety and effectiveness through a clinical trial involving 81 patients, with follow-ups at 30 days, 6 months, and 1 year, focusing on achieving low residual stenosis without major adverse events.
- Results indicated a 98.8% success rate, low rates of complications (1.2% at 30 days and 2.5% at 1 year), and highlighted the EluNIR stent as a valuable option for treating this challenging type of coronary artery issue.*
Percutaneous coronary intervention with ridaforolimus-eluting stents in long lesions: the BIONICS 38 mm prospective trial.
Coron Artery Dis
September 2023
Nephrology and Hypertension Institute, Kaplan Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Background: The ridaforolimus-eluting stent (RES) system is a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting ridaforolimus. The aim of this trial was to assess the performance of a 38 mm RES in long coronary lesions.
Methods: A prospective, multicenter, single-arm, open-label clinical trial.
Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer.
J Pers Med
April 2023
Edward Via College of Osteopathic Medicine, 350 Howard St., Spartanburg, SC 29303, USA.
Rapamycin and its derivatives are mTOR inhibitors which are FDA-approved for use as immunosuppressants and chemotherapeutic agents. These agents are currently approved to treat renal cell carcinomas, soft tissue sarcomas, and other rare tumors. As tumor treatment paradigms are moving away from organ-based drug selection and moving towards tumor characteristics for individualized treatment it is important to identify as many properties as possible that impact the efficacy of the rapalogues.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!